2m 2m 2m 2m 2m 2m 2m
Cannabis Bio (CBIH)
OTC
$0.0003$0.00 (0.00%)
Price as of Jun 03, 2026- $2.3MMarket Cap
- -50.00%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Cannabis Bio (CBIH)
$0.0003$0.00 (0.00%)
Annual
Quarterly
05/31/2025 | 05/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 303,022 +21.77% | 248,841 N/A | |
Cost of Revenue | 40,106 -12.05% | 45,599 N/A | |
Gross Profit | 262,916 +29.36% | 203,242 N/A | |
Sales and Marketing Expense | 517 -74.96% | 2,065 N/A | |
Research and Development Expense | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 684,281 -0.74% | 689,382 N/A | |
Operating Profit | -421,365 -13.32% | -486,140 N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | -127,455 -22.85% | -165,206 N/A | |
Income before Taxes | -421,365 -13.32% | -486,140 N/A | |
Income Taxes | N/A N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | N/A N/A | -651,345 N/A | |
Net Income from Continuing Operations Applicable to Common | N/A N/A | -651,345 N/A | |
Basic EPS and Net Income | -0.0001 0.00% | -0.0001 N/A | |
Diluted EPS and Net Income | -0.0001 0.00% | -0.0001 N/A | |
Basic Weighted Average Shares | 10.7B +3.86% | 10.3B N/A | |
Diluted Weighted Average Shares | 10.7B +3.86% | 10.3B N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 12,952 +1,615.50% | 755 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 12,952 +1,615.50% | 755 N/A | |
Total Current Assets | 29,085 +35.33% | 21,492 N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | N/A N/A | N/A N/A | |
Total Assets | 31,880 -44.23% | 57,162 N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 135,496 -14.42% | 158,321 N/A | |
Total Current Liabilities | 945,963 +7.26% | 881,908 N/A | |
Total Long-Term Debt | 249,500 +0.06% | 249,361 N/A | |
Total Long-Term Liabilities | 249,500 -1.87% | 254,267 N/A | |
Total Liabilities | 1.2M +5.22% | 1.1M N/A | |
Retained Earnings | -5.9M +10.29% | -5.3M N/A | |
Total Stockholders Equity | -1.2M +7.84% | -1.1M N/A | |
Total Shares Outstanding | 11.6B +11.46% | 10.4B N/A | |
Cash Flow | |||
Cash from Operating Activities | -329,627 -31.24% | -479,382 N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 341,824 -27.46% | 471,224 N/A | |
Financials Ratio | |||
Gross Margin | 86.76% N/A | N/A N/A | |
Operating Margin | -139.05% N/A | N/A N/A | |
Return on Assets | N/A N/A | N/A N/A | |
Return on Equity | N/A N/A | N/A N/A | |
Revenue Growth | 21.77% N/A | N/A N/A | |
Current Ratio | 0.03 N/A | N/A N/A | |
Cash Ratio | 0.01 N/A | N/A N/A | |
Debt-to-Equity Ratio | -0.33 N/A | N/A N/A | |
Debt-to-Assets Ratio | 12.08 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow